Trial Profile

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAY 3713372 (Primary)
Indications Adenocarcinoma; Glioblastoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Bayer

10 Sep 2026 Planned End Date changed from 17 Jun 2029 to 18 Jun 2029.
10 Sep 2026 Planned primary completion date changed from 17 Jun 2029 to 18 Jun 2029.
08 Jun 2026 Planned number of patients changed from 370 to 450.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com